Entera Bio (ENTX) Equity Ratio (2017 - 2026)

Entera Bio has disclosed Equity Ratio across 9 years of filings, most recently posting 0.81 for Q1 2026.

• Quarterly Equity Ratio fell 9.27% year-over-year to 0.81 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.81 (down 9.27% YoY) and the FY2025 annual result came in at 0.82, down 4.8% from the prior year.
• Equity Ratio declined to 0.81 in Q1 2026, from 0.82 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.92 in Q3 2022 and troughed at 0.73 in Q3 2023.
• A 5-year average of 0.86 and a median of 0.87 in 2023 frame the typical range for Equity Ratio.
• Annual changes were most pronounced in 2023 — Equity Ratio dropped 20.94% — and 2024, when it grew 14.48%.
• Tracing ENTX's Equity Ratio over 5 years: stood at 0.9 in 2022, then decreased by 1.41% to 0.88 in 2023, then slipped by 2.53% to 0.86 in 2024, then decreased by 4.8% to 0.82 in 2025, then declined by 0.63% to 0.81 in 2026.
• Business Quant data shows ENTX's Equity Ratio at 0.81 in Q1 2026, 0.82 in Q4 2025, and 0.88 in Q3 2025.